CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

CBR3 V244M is associated with LVEF reduction in breast cancer patients treated with doxorubicin

Abstract Background The CBR3 V244M single nucleotide polymorphism has been linked to the risk of anthracycline-related cardiomyopathy in survivors of childhood cancer. There have been limited prospective studies examining the impact of CBR3 V244M on the risk for anthracycline-related cardiotoxicity...

Full description

Bibliographic Details
Main Authors: Jennifer K. Lang, Badri Karthikeyan, Adolfo Quiñones-Lombraña, Rachael Hageman Blair, Amy P. Early, Ellis G. Levine, Umesh C. Sharma, Javier G. Blanco, Tracey O’Connor
Format: Article
Language:English
Published: BMC 2021-05-01
Series:Cardio-Oncology
Subjects:
Anthracycline
Breast Cancer
Carbonyl Reductase 3
Cardiotoxicity
Cardiovascular disease
Chemotherapy
Online Access:https://doi.org/10.1186/s40959-021-00103-0

Internet

https://doi.org/10.1186/s40959-021-00103-0

Similar Items